Application 761345
- Type
- BLA
- Sponsor
- PFIZER INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761345 | Elrexfio | elranatamab-bcmm | 351(a) | Rx | 2026-10-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ELREXFIO | ELRANATAMAB | SOLUTION;INJECTION | 12MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Elrexfio | ELRANATAMAB-BCMM | Pfizer Laboratories Div Pfizer Inc | f6fea598-ff58-4a20-b5e8-8a51f37d8beb | 2026-09-14 | Boxed warning, Warnings, Adverse reactions | BLA761345 |
| Elrexfio | ELRANATAMAB-BCMM | U.S. Pharmaceuticals | aa044060-5b4b-4692-bf0f-9a50e140b10e | 2026-05-14 | Boxed warning, Warnings, Adverse reactions | BLA761345 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 85545 | SUPPL | 2026-03-27 |
| 85160 | SUPPL | 2026-02-25 |
| 85159 | SUPPL | 2026-02-25 |
| 85101 | SUPPL | 2026-02-23 |
| 82817 | SUPPL | 2025-07-11 |
| 82788 | SUPPL | 2025-07-11 |
| 82765 | SUPPL | 2025-07-09 |
| 79577 | SUPPL | 2024-09-12 |
| 76821 | SUPPL | 2023-12-14 |
| 76363 | ORIG | 2023-11-06 |
| 75408 | ORIG | 2023-09-12 |
| 75405 | ORIG | 2023-09-12 |
| 75077 | ORIG | 2023-09-12 |